Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study

Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jorgensen; Peter T Dawes; Charlotte Wiell; Daniel J Wallace; Søren C Tamer; Helle Kastberg; Jørgen Petersen; Stanislaw Sierakowski

doi:10.1002/art.27524

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study

Mikkel Østergaard, Bo Baslund, William Rigby, Bernadette Rojkovich, Christian Jorgensen, Peter T Dawes, Charlotte Wiell, Daniel J Wallace, Søren C Tamer, Helle Kastberg, Jørgen Petersen, Stanislaw Sierakowski

89 Citations (Scopus)

Abstract

To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug.

Original language	English
Journal	Arthritis & Rheumatism
Volume	62
Issue number	8
Pages (from-to)	2227-38
Number of pages	12
ISSN	0004-3591
DOIs	https://doi.org/10.1002/art.27524
Publication status	Published - 1 Aug 2010

Access to Document

10.1002/art.27524

Fingerprint

Dive into the research topics of 'Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study'. Together they form a unique fingerprint.

Cite this

Østergaard, M., Baslund, B., Rigby, W., Rojkovich, B., Jorgensen, C., Dawes, P. T., Wiell, C., Wallace, D. J., Tamer, S. C., Kastberg, H., Petersen, J., & Sierakowski, S. (2010). Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis & Rheumatism, 62(8), 2227-38. https://doi.org/10.1002/art.27524

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. / Østergaard, Mikkel ; Baslund, Bo; Rigby, William et al.

In: Arthritis & Rheumatism, Vol. 62, No. 8, 01.08.2010, p. 2227-38.

Research output: Contribution to journal › Journal article › Research › peer-review

Østergaard, M , Baslund, B, Rigby, W, Rojkovich, B, Jorgensen, C, Dawes, PT, Wiell, C, Wallace, DJ, Tamer, SC, Kastberg, H, Petersen, J & Sierakowski, S 2010, 'Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study', Arthritis & Rheumatism, vol. 62, no. 8, pp. 2227-38. https://doi.org/10.1002/art.27524

Østergaard M , Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis & Rheumatism. 2010 Aug 1;62(8):2227-38. https://doi.org/10.1002/art.27524

Østergaard, Mikkel ; Baslund, Bo ; Rigby, William et al. / Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. In: Arthritis & Rheumatism. 2010 ; Vol. 62, No. 8. pp. 2227-38.

@article{4665db9dff9e4d55a3307439a02555d1,

title = "Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study",

abstract = "To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug.",

author = "Mikkel {\O}stergaard and Bo Baslund and William Rigby and Bernadette Rojkovich and Christian Jorgensen and Dawes, {Peter T} and Charlotte Wiell and Wallace, {Daniel J} and Tamer, {S{\o}ren C} and Helle Kastberg and J{\o}rgen Petersen and Stanislaw Sierakowski",

year = "2010",

month = aug,

day = "1",

doi = "10.1002/art.27524",

language = "English",

volume = "62",

pages = "2227--38",

journal = "Arthritis and Rheumatism",

issn = "0004-3591",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "8",

}

TY - JOUR

T1 - Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study

AU - Østergaard, Mikkel

AU - Baslund, Bo

AU - Rigby, William

AU - Rojkovich, Bernadette

AU - Jorgensen, Christian

AU - Dawes, Peter T

AU - Wiell, Charlotte

AU - Wallace, Daniel J

AU - Tamer, Søren C

AU - Kastberg, Helle

AU - Petersen, Jørgen

AU - Sierakowski, Stanislaw

PY - 2010/8/1

Y1 - 2010/8/1

N2 - To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug.

AB - To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug.

U2 - 10.1002/art.27524

DO - 10.1002/art.27524

M3 - Journal article

C2 - 20506254

VL - 62

SP - 2227

EP - 2238

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

SN - 0004-3591

IS - 8

ER -